Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1886-1893

  Licitra, L ^a   Perrone, F ^a   Tamborini, E ^a   Bertola, L ^a   Ghirelli, C ^a   Negri, T ^a   Orsenigo, M ^a   Filipazzi, P ^a   Pastore, E ^a   Pompilio, M ^a   Bossi, P ^a   Locati, L D ^a   Cantu', G ^a   Scaramellini, G ^a   Pilotti, S ^a   Tagliabue, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

EGFR; Head and neck cancer; Targeted therapy; Wound healing

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BIOCHEMISTRY; CANCER CELL CULTURE; CANCER RELAPSE; CELL PROLIFERATION; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; EAR NOSE THROAT SURGERY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLOSSECTOMY; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LARYNGECTOMY; MALE; MANDIBLE RESECTION; MAXILLA RESECTION; NECK DISSECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL METAPLASIA; WOUND FLUID; WOUND HEALING;

EID: 79960991414     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq756     Document Type: Article

References (21)

1. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
2. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 2004; 10: 3607-3613.
3. Braakhuis BJM, Bloemena E, Leemans CR, Brakenhoff RH. Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol 2010; 46: 485-491.
4. Schaaij-Visser TBM, Graveland AP, Gauci S et al. Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 7666-7672.
5. Braakhuis BJM, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol 2005; 15: 113-120.
6. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
7. Tagliabue E, Agresti R, Carcangiu ML et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003; 362: 527-533.
8. Perrone F, Suardi S, Pastore E et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12: 6643-6651.
9. Tamborini E, Bonadiman L, Negri T et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004; 10: 8214-8219.
10. Lagonigro MS, Tamborini E, Negri T et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006; 208: 615-623.
11. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4175.
12. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
13. Erjala K, Sundvall M, Junttila TT et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12: 4103-4111.
14. Chen Z, King W, Pearcey R et al. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008; 87: 3-16.
15. Rosenthal DI, Liu L, Lee JH et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck 2002; 24: 115-126.
16. Lin CR, Chen WS, Kruiger W et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 1984; 224: 843-848.
17. Licitra L, Rolland F, Bokemeyer C et al. Biomarker potential of EGFR gene copy number by FISH in the phase III extreme study: platinum based CT plus cetuximab in first line R/M SCCHN. ASCO Annual Meeting Proceedings 2009; 27: 302S.
18. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
19. Italiano A, Follana P, Caroli FX et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15: 649-654.
20. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-6263.
21. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731-738.